Bicara Therapeutics Inc (BCAX)

Dec 24, 2025

Hyep Ivan, Bicara Therapeutics CFO, sells $168k in BCAX stock By Investing.com - Investing.com Nigeria

Dec 24, 2025

Dec 23, 2025

Bicara Therapeutics (BCAX) Valuation After Dual Biotechnology Index Additions - Yahoo Finance

Dec 23, 2025

Dec 23, 2025

Hyep Ivan, Bicara Therapeutics CFO, sells $168k in BCAX stock - Investing.com Australia

Dec 23, 2025

Dec 23, 2025

How Bicara's Dual Biotech Index Additions Will Impact Bicara Therapeutics (BCAX) Investors - simplywall.st

Dec 23, 2025

Dec 22, 2025

The Bull Case For Bicara Therapeutics (BCAX) Could Change Following Dual Inclusion In Major Biotech Indices - Yahoo Finance

Dec 22, 2025

Dec 22, 2025

Bicara Therapeutics Inc.(NasdaqGM: BCAX) added to NASDAQ Biotechnology Index - marketscreener.com

Dec 22, 2025

Dec 21, 2025

Bicara Therapeutics Inc.(NasdaqGM:BCAX) added to S&P Biotechnology Select Industry Index - marketscreener.com

Dec 21, 2025

Dec 21, 2025

Is Bicara Therapeutics Inc. stock a defensive play in 2025July 2025 PostEarnings & Intraday High Probability Setup Alerts - Улправда

Dec 21, 2025

Dec 20, 2025

Can Bicara Therapeutics Inc. stock rebound after recent weaknessEarnings Overview Summary & Verified Swing Trading Watchlist - ulpravda.ru

Dec 20, 2025

Dec 20, 2025

Bicara Therapeutics (NASDAQ:BCAX) Raised to Hold at Mizuho - Defense World

Dec 20, 2025

Dec 20, 2025

Is Bicara Therapeutics Inc. stock trading at a premium valuationInsider Buying & AI Forecast for Swing Trade Picks - Улправда

Dec 20, 2025

Dec 20, 2025

Will Bicara Therapeutics Inc. stock deliver better than expected guidanceEarnings Recap Report & Weekly High Potential Alerts - Улправда

Dec 20, 2025

Dec 19, 2025

Published on: 2025-12-19 16:38:22 - Bölüm Sonu Canavarı

Dec 19, 2025

Dec 19, 2025

Bicara Therapeutics (NASDAQ:BCAX) Raised to "Hold" at Mizuho - MarketBeat

Dec 19, 2025

Dec 19, 2025

Will Bicara Therapeutics Inc. stock continue dividend increasesJuly 2025 Sentiment & Fast Entry High Yield Stock Tips - Улправда

Dec 19, 2025

Dec 18, 2025

What makes Bicara Therapeutics Inc. stock attractive to growth fundsFed Meeting & Technical Pattern Recognition Alerts - Улправда

Dec 18, 2025

Dec 18, 2025

Can Bicara Therapeutics Inc. stock reach $100 price target2025 Earnings Impact & Long-Term Investment Growth Plans - ulpravda.ru

Dec 18, 2025

Dec 18, 2025

Mizuho Initiates Coverage of Bicara Therapeutics (BCAX) with Neutral Recommendation - Nasdaq

Dec 18, 2025

Dec 18, 2025

Mizuho Initiates Bicara Therapeutics at Neutral With $18 Price Target - marketscreener.com

Dec 18, 2025

Dec 18, 2025

Bicara Therapeutics (BCAX) Receives Neutral Rating from Mizuho | - GuruFocus

Dec 18, 2025

Dec 17, 2025

Mizuho initiates Bicara Therapeutics stock coverage with Neutral rating By Investing.com - Investing.com Canada

Dec 17, 2025

Dec 17, 2025

Mizuho initiates Bicara Therapeutics stock coverage with Neutral rating - Investing.com

Dec 17, 2025

Dec 17, 2025

Bicara Therapeutics initiated with a Neutral at Mizuho - TipRanks

Dec 17, 2025

Dec 16, 2025

Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 12,500 Shares - MarketBeat

Dec 16, 2025

Dec 15, 2025

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 - The Manila Times

Dec 15, 2025

Dec 11, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 11, 2025

Dec 11, 2025

Bicara Therapeutics Earns Relative Strength Rating Upgrade - Investor's Business Daily

Dec 11, 2025

Dec 10, 2025

Bicara announces preliminary data from phase 1b cohort of ficerafusp alfa - MSN

Dec 10, 2025

Dec 10, 2025

There is no doubt that Bicara Therapeutics Inc (BCAX) ticks all the boxes. - setenews.com

Dec 10, 2025

Dec 08, 2025

Bicara stock maintains Buy rating at Stifel after ESMO-Asia data - Investing.com Australia

Dec 08, 2025

Dec 08, 2025

Published on: 2025-12-09 02:41:05 - moha.gov.vn

Dec 08, 2025

Dec 08, 2025

Promising Efficacy and Investment Potential for Bicara Therapeutics’ FICERA in Combination with Keytruda - TipRanks

Dec 08, 2025

Dec 08, 2025

Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation - TipRanks

Dec 08, 2025

Dec 08, 2025

Bicara Therapeutics Reports Promising Phase 1b Data - TipRanks

Dec 08, 2025

Dec 08, 2025

Bicara Therapeutics Advances Dose Optimization of Potential Neck, Head Cancer Treatment - marketscreener.com

Dec 08, 2025

Dec 08, 2025

Bicara Therapeutics Inc Announces Preliminary Phase 1b Data - TradingView — Track All Markets

Dec 08, 2025

Dec 07, 2025

Promising Phase 1/1b Results and Future Prospects Boost Bicara Therapeutics’ Buy Rating - TipRanks

Dec 07, 2025

Dec 07, 2025

Bicara announces preliminary data from Phase 1b cohort of ficerafusp alfa - TipRanks

Dec 07, 2025

Dec 06, 2025

Bicara Therapeutics (Nasdaq: BCAX) Phase 1b data guide FORTIFI-HN01 dose decision for 2026 - Stock Titan

Dec 06, 2025

Dec 06, 2025

Bicara Therapeutics Inc. $BCAX Shares Acquired by Schroder Investment Management Group - MarketBeat

Dec 06, 2025

Dec 05, 2025

Bicara Therapeutics (BCAX): Reassessing Valuation After Breakthrough Therapy Designation and Strong Phase 1b Data - Yahoo Finance

Dec 05, 2025

Dec 05, 2025

Will Bicara Therapeutics Inc. stock sustain high P E ratios2025 Biggest Moves & Verified Entry Point Detection - Newser

Dec 05, 2025

Dec 03, 2025

Skandinaviska Enskilda Banken AB publ Acquires 61,201 Shares of Bicara Therapeutics Inc. $BCAX - MarketBeat

Dec 03, 2025

Dec 02, 2025

Bicara Therapeutics (BCAX) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025

Dec 02, 2025

Does Bicara Therapeutics Inc (BCAX) offer a good opportunity for investors? - Setenews

Dec 02, 2025